AZN
AstraZeneca (AZN) Q1 2026 Earnings
AZN·Reported April 29, 2026·Before market open
AstraZeneca reported Q1 2026 revenue of $15.3B (+12.5% YoY), beat analyst consensus of $14.9B by $355.5M. Diluted EPS came in at $2.58 (+4.0% YoY), beat the $2.57 consensus by $0.01.
Revenue
$15.3Bbeat by $355.5M
Consensus: $14.9BDiluted EPS
$2.58beat by $0.01
Consensus: $2.57
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q1 2026 Earnings FAQ
Common questions about AstraZeneca's Q1 2026 earnings report.
AstraZeneca (AZN) reported Q1 2026 earnings on April 29, 2026 before market open.
AstraZeneca reported revenue of $15.3B and diluted EPS of $2.58 for Q1 2026.
Revenue beat the consensus estimate of $14.9B by $355.5M. EPS beat the consensus estimate of $2.57 by $0.01.
Compared to the same quarter a year prior, revenue grew 12.5% from $13.6B a year earlier and diluted EPS grew 4.0% from $2.48.